Notice2022-24805
David Elias Mendoza: Final Debarment Order
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 15, 2022
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring David Elias Mendoza for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Mendoza engaged in a pattern of importing or offering for import misbranded drugs (i.e., in an amount, frequency, or dosage that is inconsistent with his personal or household use) that are not designated in an authorized electronic data interchange system as products regulated by FDA. Mr. Mendoza was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of March 28, 2022 (30 days after receipt of the notice), Mr. Mendoza had not responded. Mr. Mendoza's failure to respond and request a hearing within the timeframe prescribed by regulation constitutes a waiver of his right to a hearing and any contentions concerning this matter.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 219 (Tuesday, November 15, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 219 (Tuesday, November 15, 2022)]
[Notices]
[Pages 68503-68504]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-24805]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0526]
David Elias Mendoza: Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing an order
under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring
David Elias Mendoza for a period of 5 years from importing or offering
for import any drug into the United States. FDA bases this order on a
finding that Mr. Mendoza engaged in a pattern of importing or offering
for import misbranded drugs (i.e., in an amount, frequency, or dosage
that is inconsistent with his personal or household use) that are not
designated in an authorized electronic data interchange system as
products regulated by FDA. Mr. Mendoza was given notice of the proposed
debarment and was given an opportunity to request a hearing to show why
he should not be debarred. As of March 28, 2022 (30 days after receipt
of the notice), Mr. Mendoza had not responded. Mr. Mendoza's failure to
respond and request a hearing within the timeframe prescribed by
regulation constitutes a waiver of his right to a hearing and any
contentions concerning this matter.
DATES: This order is applicable November 15, 2022.
ADDRESSES: Submit applications for termination of debarment to the
Dockets Management Staff, Food and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, or at <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of
Enforcement (ELEM-4144), Office of Strategic Planning and Operational
Policy, Office of Regulatory Affairs, Food and Drug Administration,
12420 Parklawn Dr., Rockville, MD 20857, 240-402-8743, or at
<a href="/cdn-cgi/l/email-protection#c3a7a6a1a2b1aea6adb7b083a5a7a2edababb0eda4acb5"><span class="__cf_email__" data-cfemail="6105040300130c040f1512210705004f0909124f060e17">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(D) of the FD&C Act (21 U.S.C. 335a(b)(1)(D))
permits debarment of an individual from importing or offering for
import any drug into the United States if FDA finds, as required by
section 306(b)(3)(D) of the FD&C Act, that the individual has engaged
in a pattern of importing or offering for import misbranded drugs
(i.e., in an amount, frequency, or dosage that is inconsistent with
personal or household use by the importer) that are not designated in
an authorized electronic data interchange system as products regulated
by FDA.
After an investigation, FDA discovered that Mr. Mendoza has engaged
in numerous instances of importing or offering for import misbranded
drugs (i.e., in an amount, frequency, or dosage that is inconsistent
with his personal or household use) that were not designated in an
authorized electronic data interchange system as products that are
regulated by FDA; all the parcels containing the misbranded drugs
serving as the basis for this action, described in further detail
below, were intercepted by FDA at the John F. Kennedy (JFK)
International Mail Facility (IMF) and were addressed to Mr. Mendoza at
one of two addresses connected to him.
On or about June 4, 2019, Mr. Mendoza offered for import a parcel
that contained 250 tablets of CENFORCE-100, which was a misbranded drug
because the product was determined to be a prescription drug product
that failed to contain the ``Rx-only'' symbol on its label and lacked
adequate directions for use in its labeling. The product was refused
entry on July 9, 2019.
On or about January 24, 2020, Mr. Mendoza offered for import a
parcel that contained 250 tablets of CENFORCE-100, which was a
misbranded drug because the product was determined to be a prescription
drug product that failed to contain the ``Rx-only'' symbol on its label
and lacked adequate directions for use in its labeling. The product was
refused entry on February 20, 2020.
On or about January 29, 2020, Mr. Mendoza offered for import a
parcel that contained 250 tablets of CENFORCE-100, which was a
misbranded drug because the product was determined to be a prescription
drug product that failed to contain the ``Rx-only'' symbol on its label
and lacked adequate directions for use in its labeling. The product was
refused entry on February 25, 2020.
On or about January 30, 2020, Mr. Mendoza offered for import a
parcel that contained 270 tablets of CENFORCE-100, which was a
misbranded drug because the product was determined to be a prescription
drug product that failed to contain the ``Rx-only'' symbol on its label
and lacked adequate directions for use in its labeling. The product was
refused entry on February 25, 2020.
On or about February 14, 2020, Mr. Mendoza offered for import a
parcel that contained 330 tablets of CENFORCE-100, which was a
misbranded drug because the product was determined to be a prescription
drug product that failed to contain the ``Rx-only'' symbol on its label
and lacked adequate directions for use in its labeling. The product was
refused entry on March 17, 2020.
On or about February 14, 2020, Mr. Mendoza offered for import a
parcel that contained 250 tablets of CENFORCE-100, which was a
misbranded drug because the product was determined to be a prescription
drug product that failed to contain the ``Rx-only'' symbol on its label
and lacked adequate directions for use in its labeling. The product was
refused entry on March 17, 2020.
On or about February 24, 2020, Mr. Mendoza offered for import a
parcel that contained 250 tablets of CENFORCE-100, which was a
misbranded drug because the product was determined to be a prescription
drug product that failed to contain the ``Rx-only'' symbol on its label
and lacked adequate directions for use in its labeling. The product was
refused entry on March 19, 2020.
On or about June 10, 2020, Mr. Mendoza offered for import a parcel
that contained 300 tablets of CENFORCE-100, which was a misbranded drug
because the product was determined to be a prescription drug product
that failed to contain the ``Rx-only'' symbol on its label. The product
was refused entry on July 10, 2020.
On or about June 10, 2020, Mr. Mendoza offered for import a parcel
that contained 300 tablets of CENFORCE-100, which was a misbranded drug
because the product was determined to be a prescription drug product
that failed to contain the ``Rx-only'' symbol on its label. The product
was refused entry on July 7, 2020.
On or about June 16, 2020, Mr. Mendoza offered for import a parcel
that contained 300 tablets of CENFORCE-100, which was a misbranded drug
because the product failed to contain adequate directions for use in
its labeling. The product was refused entry on July 14, 2020.
On or about June 16, 2020, Mr. Mendoza offered for import a parcel
that contained 320 tablets of CENFORCE-100, which was a misbranded drug
[[Page 68504]]
because the product failed to contain adequate directions for use in
its labeling. The product was refused entry on July 14, 2020.
On or about June 18, 2020, Mr. Mendoza offered for import a parcel
that contained 300 tablets of CENFORCE-100, which was a misbranded drug
because the product was determined to be a prescription drug product
that failed to contain the ``Rx-only'' symbol on its label. The product
was refused entry on July 15, 2020.
As a result of Mr. Mendoza's pattern of importing or offering for
import misbranded drugs (i.e., in an amount, frequency, or dosage that
is inconsistent with his personal or household use) that are not
designated in an authorized electronic data interchange system as
products regulated by FDA, in accordance with section 306(b)(3)(D) of
the FD&C Act, FDA sent Mr. Mendoza, by certified mail on February 17,
2022, a notice proposing to debar him for a 5-year period from
importing or offering for import any drug into the United States.
In proposing a debarment period, FDA weighed the considerations set
forth in section 306(c)(3) of the FD&C Act that it considered
applicable to Mr. Mendoza's pattern of conduct and concluded that his
conduct warranted the imposition of a 5-year period of debarment.
The proposal informed Mr. Mendoza of the proposed debarment and
offered him an opportunity to request a hearing, providing 30 days from
the date of receipt of the letter in which to file the request, and
advised him that failure to request a hearing constituted a waiver of
the opportunity for a hearing and of any contentions concerning this
action. Mr. Mendoza received the proposal and notice of opportunity for
a hearing on February 26, 2022. Mr. Mendoza failed to request a hearing
within the timeframe prescribed by regulation and has, therefore,
waived his opportunity for a hearing and waived any contentions
concerning his debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Assistant Commissioner, Office of Human and Animal
Food Operations, under section 306(b)(3)(D) of the FD&C Act, under
authority delegated to the Assistant Commissioner, finds that Mr. David
Elias Mendoza has engaged in a pattern of importing or offering for
import misbranded drugs (i.e., in an amount, frequency, or dosage that
is inconsistent with his personal or household use) that are not
designated in an authorized electronic data interchange system as
products regulated by FDA. FDA finds that this pattern of conduct
should be accorded a debarment period of 5 years as provided by section
306(c)(2)(A)(iii) of the FD&C Act.
As a result of the foregoing finding, Mr. Mendoza is debarred for a
period of 5 years from importing or offering for import any drug into
the United States, effective (see DATES). Pursuant to section 301(cc)
of the FD&C Act (21 U.S.C. 331(cc)), the importing or offering for
import into the United States of any drug or controlled substance by,
with the assistance of, or at the direction of Mr. Mendoza is a
prohibited act.
Any application by Mr. Mendoza for termination of debarment under
section 306(d)(1) of the FD&C Act should be identified with Docket No.
FDA-2021-N-0526 and sent to the Dockets Management Staff (see
ADDRESSES). The public availability of information in these submissions
is governed by 21 CFR 10.20(j).
Publicly available submissions will be placed in the docket and
will be viewable at <a href="https://www.regulations.gov">https://www.regulations.gov</a> or at the Dockets
Management Staff (see ADDRESSES) between 9 a.m. and 4 p.m., Monday
through Friday, 240-402-7500.
Dated: November 9, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-24805 Filed 11-14-22; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 15, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.